CalciMedica to Host a Call to Review Full Data Set, Including a Win Ratio Analysis, From Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP)
CalciMedica to Host a Call to Review Full Data Set, Including a Win Ratio Analysis, From Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP)
Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT
電話會議和網絡直播將於2024年10月30日週三中午12點（東部時間）/上午9點（太平洋時間）舉行
LA JOLLA, Calif., Oct. 28, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a call on Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT to review the full data set and win ratio analysis from the Company's Phase 2b CARPO trial of Auxora in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). Prof. Robert Sutton, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust and chair of the Steering Committee for the CARPO trial, will deliver his plenary presentation from the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, entitled "A Randomized, Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in Patients with AP and Accompanying SIRS - CARPO."
加利福尼亞州拉霍亞，2024年10月28日/美通社/--CalciMedica公司（「CalciMedica」）（納斯達克: 中國飛機租賃），一家臨床階段生物藥物公司，致力於開發新型鈣釋放激活性鈣（CRAC）通道抑制療法，用於急性和慢性炎症及免疫疾病，今日宣佈將於2024年10月30日週三中午12點（東部時間）/上午9點（太平洋時間）召開電話會議，審查公司在急性胰腺炎（AP）中Auxora的第20億CARPO實驗的完整數據集和贏利比分析，伴隨全身性炎症反應綜合徵（SIRS）。利物浦大學和利物浦大學醫院NHS基金會託管委員會主席，CARPO實驗指導委員會主席羅伯特·薩頓教授將在美國胃腸病學學院（ACG）2024年年會上作全體演講，題爲「在AP患者中的Auxora隨機、雙盲、安慰劑對照劑量範圍研究- CARPO」。
Conference Call and Webcast Details
Stockholders and other interested parties may access the call by following the instructions below. A live webcast of the event can also be accessed in the "Upcoming Events" section of CalciMedica's IR website at . The archived webcast will be available following the completion of the event.
電話會議和網絡直播細節
股東和其他感興趣的方可以按照以下說明接入電話會議。活動的現場網絡直播也可以在CalciMedica的IR網站的「即將舉行的活動」部分中訪問。活動結束後，存檔的網絡直播將可供查看。
Participant Webcast Link:
參與者網絡直播鏈接:
Click on the webcast link and complete the online registration form.
單擊網絡直播鏈接，填寫在線註冊表格。
Upon registering, you will be connected to the online webcast.
註冊後，您將被連接到在線網絡直播。
Participant Dial-in Numbers: 1-646-357-8785 (US) and 1-800-836-8184 (international)
參與者撥入號碼: 1-646-357-8785 (美國) 和 1-800-836-8184 (國際)
If prompted by the operator, ask to join the CalciMedica Phase 2b CARPO Full Data Set & Win Ratio call.
如運營商提示，請索要加入CalciMedica第20億期CARPO完整數據集和勝率呼叫。
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in patients with AP with SIRS and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with AKI with associated AHRF and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in patients with AIPT. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit .
CalciMedica是一家致力於開發新型CRAC通道抑制劑治療炎症和免疫疾病的臨床生物製藥公司。CalciMedica的專有技術針對CRAC通道的抑制作用可調節免疫反應，從而保護組織細胞，有潛力在當前沒有已批准療法的危及生命的炎症和免疫性疾病中提供治療效益。CalciMedica的主要產品候選藥物Auxora已經在多項完成的療效性臨床試驗中展現出積極和一致的臨床結果，對於第二期臨床試驗具有參考意義。奇泊 -NCT04681066）和冠狀病毒性肺炎患者的第2期臨床試驗（名爲CARDEA -NCT04345614）已經完成，繼續支持正在進行的第1/2AIPT研究（名爲CRSPA -NCT04195347），預計在2025年公佈數據，並已啓動其第2項研究（名爲KOURAGE -NCT06374797），預計在2025年公佈基於與AHRF相關的AKI的數據。 CalciMedica由來自Torrey Pines Therapeutics和哈佛CBR生物醫學研究所的科學家創立，總部位於加利福尼亞州拉荷亞。有關更多信息，請訪問。
CalciMedica是一家臨床階段的生物製藥公司，專注於開發新型CRAC通道抑制療法，用於治療炎症和免疫性疾病。CalciMedica的專有技術針對CRAC通道抑制以調節免疫反應並保護組織細胞免受損傷，有潛力在目前沒有批准療法的威脅生命的炎症和免疫性疾病中提供治療益處。CalciMedica的主力產品候選藥Auxora在多項已完成的功效性臨床試驗中展示了積極和一致的臨床結果。CalciMedica已經宣佈了阿波斯NCT04681066）患有AP和SIRS的患者的第20億期試驗的頭部數據，並完成了針對COVID肺炎患者的第2期試驗（稱爲CARDEA – NCT04345614）該公司目前正在對患有與AHRF相關的AKI的患者進行第2期試驗（名爲KOURAGE – NCT06374797），並繼續支持進行中的針對AIPt患者的第1/2期試驗（名爲CRSPA – NCT04195347）。CalciMedica由來自Torrey Pines Therapeutics和哈佛生物醫藥研究所的科學家創立，並總部設在加利福尼亞州拉霍亞。更多信息，請訪問。
CalciMedica Contact:
CalciMedica聯繫方式：Sarah Sutton / Kevin Murphy
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
[email protected]
(212) 600-1902
投資者和媒體
阿哥特合夥人。
來源：CalciMedica, Inc.
[email protected]
（212）600-1902
SOURCE CalciMedica, Inc.
源自CalciMedica，Inc。
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
